Director
Novartis, New Jersey
Rob Dodge has worked in CMC manufacturing developing analytical release assays for Biologic therapeutics and Bioanalytical laboratories developing and carrying out regulated bioanalytical analysis of small molecule and protein drugs, as well as protein biomarkers and analysis of novel molecular entities such as nucleic acids, cell therapy, CRISPR, and gene therapy products. Rob is currently the Director Scientific Governance – Low Molecular Weight and Biological Products at Novartis with his team working across the development portfolio from late Discovery to Marketed products.
Prologue: Biomarker and Omics Approaches
ON DEMAND
The Bioanalytical Profile for a DARPin Therapeutic: Pharmacokinetics and Immunogenicity.
Tuesday, October 24, 2023
3:15 PM – 3:30 PM ET
AAPS Bioanalytical Community Membership Meeting
Tuesday, October 24, 2023
5:00 PM – 6:00 PM ET
Symposium: The Bioanalytical Lab of the Future 2
Wednesday, October 25, 2023
9:00 AM – 11:00 AM ET
Rapid Fires: The Bioanalytical Lab of the Future 1
Wednesday, October 25, 2023
3:00 PM – 4:00 PM ET